预先存在的免疫力驱动了对食道腺癌中新辅助化疗的反应

Giuseppina Arbore1,2, Luca Albarello3, Gabriele Bucci4

  • 1Experimental Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Cancer research
|June 23, 2023
PubMed
概括

在食道腺癌 (EAC) 中先前存在的免疫力预测了对新辅助化疗 (nCT) 的反应. 识别这些免疫特征可以帮助分层患者进行量身定制的治疗,并改善生存结果.

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
208